𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma

✍ Scribed by Lakshmi Rajdev; Gary Goldberg; Una Hopkins; Joseph A. Sparano

Book ID
111641091
Publisher
Springer US
Year
2006
Tongue
English
Weight
330 KB
Volume
23
Category
Article
ISSN
1357-0560

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase I trial of dactinomycin intraven
A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies
✍ Martin S. Blumenreich; Thomas M. Woodcock; Stephen P. Richman; Mariesa K. Jones; πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 204 KB πŸ‘ 3 views

Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-90) on the Karnofsky scale. Act D was administered

A phase II trial of gemcitabine in patie
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma
✍ Charles S. Fuchs; Jeffrey W. Clark; David P. Ryan; Mathew H. Kulke; Haesook Kim; πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 74 KB πŸ‘ 2 views

## Abstract ## BACKGROUND There is no effective systemic therapy for patients with hepatocellular carcinoma. A recent trial reported a moderate antitumor activity for gemcitabine among Asian patients with advanced hepatocellular carcinoma. This led to our examination of the efficacy and tolerabili